Gilder Gagnon Howe & Co’s CG Oncology CGON Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,523	Closed	-$813K	–	257
2024 Q1	$813K	Buy	+18,523	New	+$756K	0.01%	220

Other funds holding CGON

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Yu Fan $97M AUM 57.2% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Gilder Gagnon Howe & Co's CGON Position: Q2 2024 in Review

Gilder Gagnon Howe & Co sold out of CG Oncology (CGON) in Q2 2024, closing a stake of 18,523 shares — an estimated $813K sold.

Gilder Gagnon Howe & Co first reported a position in CGON in Q1 2024 and held it in 1 quarter. The position peaked at $813K in Q1 2024. 111 funds tracked by Wall St. Rank hold CGON as of Q2 2024.

Gilder Gagnon Howe & Co reported no remaining CG Oncology position as of Q2 2024 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 18,523 CG Oncology shares in Q2 2024, an estimated $813K.
Gilder Gagnon Howe & Co first reported a position in CG Oncology in Q1 2024 and held it in 1 quarter.
Gilder Gagnon Howe & Co's CG Oncology position peaked at $813K in Q1 2024.
111 funds tracked by Wall St. Rank held CG Oncology as of Q2 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2024, filed 14 Aug 2024.